Overview

Theranostics: 68GaDOTATOC and 90YDOTATOC

Status:
Unknown status
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
Participants in this research study have tumors that express somatostatin receptors such as neuroendocrine tumors, medulloblastoma, meningioma, and neuroblastoma. Approximately 64 people will participate in this study conducted at the University of Iowa.
Phase:
Phase 2
Details
Lead Sponsor:
Sue O'Dorisio
University of Iowa
Collaborators:
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Treatments:
Amino-acid, glucose, and electrolyte solution
Edotreotide
Octreotide
Radiopharmaceuticals
Somatostatin